TY - JOUR
T1 - Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs
T2 - British Society for Rheumatology guideline scope
AU - Tillett, William
AU - Allen, Alexander
AU - Tucker, Laura
AU - Chandler, David
AU - Ciurtin, Coziana
AU - Davis, Charlotte
AU - Dick, Andrew
AU - Foulkes, Amy
AU - Gullick, Nicola
AU - Helliwell, Philip
AU - Jadon, Deepak
AU - Jones, Gareth
AU - Kyle, Stuart
AU - Madhok, Vishnu
AU - McHugh, Neil
AU - Parkinson, Andrew
AU - Raine, Tim
AU - Siebert, Stefan
AU - Smith, Catherine
AU - Coates, Laura C
N1 - © The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: [email protected].
PY - 2021/4/30
Y1 - 2021/4/30
N2 - The aim of this guideline is to provide an update on evidence-based recommendations for treatment of adult patients with PsA. The previous BSR guidelines for PsA were published in 2012 and since that time, there have been many new advanced therapies licensed for PsA. This update will provide practical guidance for clinicians on the optimal selection of advanced therapies taking into account different domains of PsA (arthritis, enthesitis, dactylitis, axial disease and psoriasis) and key associated comorbidities. It will also update guidance on treatment strategy including the use of a treat-to-target approach. The guideline will be developed using the methods and processes outlined in Creating Clinical Guidelines: Our Protocol. (1) This development process to produce guidance, advice and recommendations for practice has National Institute for Health and Care Excellence (NICE) accreditation.
AB - The aim of this guideline is to provide an update on evidence-based recommendations for treatment of adult patients with PsA. The previous BSR guidelines for PsA were published in 2012 and since that time, there have been many new advanced therapies licensed for PsA. This update will provide practical guidance for clinicians on the optimal selection of advanced therapies taking into account different domains of PsA (arthritis, enthesitis, dactylitis, axial disease and psoriasis) and key associated comorbidities. It will also update guidance on treatment strategy including the use of a treat-to-target approach. The guideline will be developed using the methods and processes outlined in Creating Clinical Guidelines: Our Protocol. (1) This development process to produce guidance, advice and recommendations for practice has National Institute for Health and Care Excellence (NICE) accreditation.
U2 - 10.1093/rheumatology/keaa526
DO - 10.1093/rheumatology/keaa526
M3 - Article
C2 - 33097948
SN - 1462-0324
VL - 60
SP - 1588
EP - 1592
JO - Rheumatology (Oxford, England)
JF - Rheumatology (Oxford, England)
IS - 4
M1 - keaa526
ER -